Gannex received US IND approval for its NASH Drug Candidate ASC42

This article was originally published here

ASC42 is an in-house developed novel non-steroidal, selective, potent Farnesoid X Receptor (FXR) agonist with best-in-class potential. In two NASH animal models, ASC42 demonstrated significant improvements in liver

The post Gannex received US IND approval for its NASH Drug Candidate ASC42 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply